Study identifier:D2600C00004
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
A Phase I, Single Centre, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability and Pharmacokinetics of Oral AZD2423 Solution after Administration of Multiple Ascending Doses for 12 days in Young and Elderly Healthy Japanese Volunteers
Healthy
Phase 1
Yes
AZD2423, Placebo
All
19
Interventional
20 Years - 80 Years
Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Basic Science
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
No locations available
Arms | Assigned Interventions |
---|---|
Experimental: 1 | Drug: AZD2423 oral solution |
Placebo Comparator: 2 | Drug: Placebo oral solution |